EP1140155A4 - Improved recombinant hepatitis b surface antigen - Google Patents

Improved recombinant hepatitis b surface antigen

Info

Publication number
EP1140155A4
EP1140155A4 EP99966613A EP99966613A EP1140155A4 EP 1140155 A4 EP1140155 A4 EP 1140155A4 EP 99966613 A EP99966613 A EP 99966613A EP 99966613 A EP99966613 A EP 99966613A EP 1140155 A4 EP1140155 A4 EP 1140155A4
Authority
EP
European Patent Office
Prior art keywords
surface antigen
recombinant hepatitis
improved recombinant
improved
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99966613A
Other languages
German (de)
French (fr)
Other versions
EP1140155A1 (en
Inventor
Qinjian Zhao
Robert Sitrin
Dicky G Abraham
David P Gervais
Juan Giminez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1140155A1 publication Critical patent/EP1140155A1/en
Publication of EP1140155A4 publication Critical patent/EP1140155A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP99966613A 1998-12-23 1999-12-22 Improved recombinant hepatitis b surface antigen Withdrawn EP1140155A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11340098P 1998-12-23 1998-12-23
US113400P 1998-12-23
PCT/US1999/030770 WO2000037104A1 (en) 1998-12-23 1999-12-22 Improved recombinant hepatitis b surface antigen

Publications (2)

Publication Number Publication Date
EP1140155A1 EP1140155A1 (en) 2001-10-10
EP1140155A4 true EP1140155A4 (en) 2004-11-03

Family

ID=22349182

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99966613A Withdrawn EP1140155A4 (en) 1998-12-23 1999-12-22 Improved recombinant hepatitis b surface antigen

Country Status (5)

Country Link
EP (1) EP1140155A4 (en)
JP (1) JP2002532116A (en)
AU (1) AU2212100A (en)
CA (1) CA2355680A1 (en)
WO (1) WO2000037104A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
UA79735C2 (en) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Purification of hbv antigens for use in vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707542A (en) * 1983-08-22 1987-11-17 Merck & Co., Inc. Immunogenic HbsAg derived from transformed yeast
EP0314240A2 (en) * 1987-10-26 1989-05-03 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101651A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Hepatitis b virus surface proteins with reduced host carbohydrate content
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707542A (en) * 1983-08-22 1987-11-17 Merck & Co., Inc. Immunogenic HbsAg derived from transformed yeast
EP0314240A2 (en) * 1987-10-26 1989-05-03 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0037104A1 *
WAMPLER DE ET AL.: "Multiple chemical forms of hepatitis B surface antigen produced in yeast.", PROC. NATL. ACAD. SCI. USA, vol. 82, October 1985 (1985-10-01), pages 6830 - 6834, XP002295841 *

Also Published As

Publication number Publication date
JP2002532116A (en) 2002-10-02
EP1140155A1 (en) 2001-10-10
AU2212100A (en) 2000-07-12
CA2355680A1 (en) 2000-06-29
WO2000037104A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
HUP0100094A3 (en) Novel surface antigen
DE69940817D1 (en) Hepatitis c tripeptide inhibitoren
DE69929887D1 (en) Hepatitis c inhibitor peptide
HU230007B1 (en) Antigenic peptides derived from telomerase
EP1073464A4 (en) Monoclonal antibodies with reduced immunogenicity
EP1083883A4 (en) Stabilizers for lyophilized vaccines
GB2334723B (en) Hard surface cleaner
GB0127673D0 (en) Polypeptide
GB2342596B (en) Vacuum cleaner
IL139269A0 (en) Hepatitis vaccine
EP1140155A4 (en) Improved recombinant hepatitis b surface antigen
CA84804S (en) Vacuum cleaner
HUP0003511A3 (en) Hepatitis b virus polypeptides
GB9825184D0 (en) Antigen
AU2232399A (en) Recombinant ctb-based vaccines
GB9726147D0 (en) Antigens
GB2327585B (en) Surface construction
GB9825053D0 (en) Recombinant virus
GB9522485D0 (en) Hepatitis b surface antigen variants
GB9800760D0 (en) Antigens
AU2047P (en) Eskdale Poa labillardieri
GB9702621D0 (en) Surface cleaner
GB9813560D0 (en) Hepatitis C Receptor Protein
GB9819387D0 (en) Polypeptide
GB9822143D0 (en) Antigens

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010723;LT PAYMENT 20010723;LV PAYMENT 20010723;MK PAYMENT 20010723;RO PAYMENT 20010723;SI PAYMENT 20010723

A4 Supplementary search report drawn up and despatched

Effective date: 20040922

17Q First examination report despatched

Effective date: 20050404

17Q First examination report despatched

Effective date: 20050404

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080404